🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

And here are finally the 5-year results of Evolut Low Risk, a trial in which the self-expanding prosthesis holds its own against surgery. A trial where, let’s remember, the average age was 74 years. For years, to the question: 'How long does a TAVI prosthesis last?' we didn’t

In #ISCHEMIA trial, spontaneous #cvMI was assoc. w/⬇️ early & late generic & disease-specific #QoL. Procedural MI was only assoc. w/ a transient ⬇️reduction in disease-specific QoL. jacc.org/doi/10.1016/j.… #CardioX #JACCINT Gregg W. Stone MD Giuseppe Biondi-Zoccai Dr. Deepak L. Bhatt Tulio Caldonazo

Happened in the past days Università Cattolica. #training center of #policlinicogemelli busy with our #cardiovascular department. 1. White lab for cardiac surgery fellows to learn #CABG 2. bench #TAVR station for young cardiologists to practice #TAVI deployment Very pleasant to see!

What is the global economic burden of heart failure? Discover more in #EHJ 👉 ow.ly/ZTNS50W4JG4 Rocco Montone EHJ Editor-in-Chief #heartfailure

First Gemelli Training Center #TAVI course focused on vascular safety completed! …including 2 live #TAVR cases in pts with hostile vascular anatomy… Thank you to all the team !!!

Easy Hematoma Classification After Transradial PCI

Calcium in 3D—using angiography alone. A novel approach to visualizing coronary calcium with #3DStent GE HealthCare 💭 How would you treat this? IVL? Other strategy? PCRonline 🫀 TCTMD jcspratt Ziad Ali Natalia Pinilla Lorenzo Azzalini Nicolas Amabile Yader Sandoval Javier Escaned

Can we say that #PCI looks at least promising for ischemic #cardiomyopathy ?

How dramatic is this! Don,t often see dynamic CTA of a type A dissection.

Today we celebrate an important and exciting milestone as the PROTECT IV study completes enrollment with 1252 subjects randomized! This achievement would not have been possible without the support of each PROTECT IV site. We value and appreciate your collective contributions to

Yesterday we had the priviledge of successfully performing the last trial’s #Impella -protected #PCI at Gemelli Hospital!!!! Looking forward to see the results of this pivotal (potentially guidelines-changing) clinical trial !!!

I am pleased to announce that the new Impact Factor of EuroIntervention is the highest in its 20-year history: 9.5. Ranked 16th out of 230 journals in the cardiovascular category (+5 positions versus the previous year). Thank you all — it’s an exciting rollercoaster.

This image is a schematic diagram illustrating specific transport defects associated with various renal tubular disorders. Manual Of Medicine

Proud to include the first patient in the EBC DCB study. Soledad Ojeda Javier Suarez d Lezo Javi Moreiras Belén Cid Alvarez Nieves Gonzalo ACI-SEC: Hemodinamica Rafael González Manzanares FRANCESCO BURZOTTA Neisser M Evandro Martins F. MD Goran Stankovic, MD, PhD @davidhild David Hildick-Smith Alfonso Jurado-Román jose diaz Pablo J. Baglioni 🇦🇷 Antonio Gomez Menchero PCRonline 🫀

Mixed valvular heart disease: moderate stenosis and regurgitation may represent severe disease. Echo is the first step, but multimodality imaging and assessment of global impact are key. Read more in #EHJ. doi.org/10.1093/eurhea… #valve #cardiotwitter European Society of Cardiology Journals European Society of Cardiology

#EAPCI Online Coaching Programme 🌟 🎉We are launching 3️⃣ different calls 1️⃣ <40 years of age 2️⃣ for the ones returning to clinical practice from sick, maternity or paternity leave; 3️⃣for the ones practicing in countries classified by the World Bank as low and lower-middle

10y outcomes on S3 #TAVR vs SAVR in intermediate risk pts in P2A S3i is out #NYValves2025! Tamim Nazif presented similar site reported ☠️ (~80% dead in 10y with mean age 80) and low reintervention (3 and 3.2%) between two groups among survivors. It gives us a good picture of the

IDEAL-LM 5-year results: In patients undergoing PCI for left main disease, biodegradable-polymer DES + 4mo DAPT showed no advantage over durable-polymer DES + 12mo DAPT. MACE, MI, TVR, and ST rates were similar. #EAPCI #LMPCI #DES #DAPT ow.ly/W1QI50W4OXj

15-year data 📅 from the PROLONG registry 📚 show transcatheter #PFO closure is safe ✅ and effective in preventing recurrent stroke and embolism in cryptogenic cases, with very low complication rates ⚠️. Real-world win! jacc.org/doi/10.1016/j.… #Stroke